Dr. Oren received her MD degree from the Sackler School of Medicine, Tel Aviv University, Israel and completed her internship at Tel Aviv Medical Center. Currently at NeuroDerm, she is directing the full range of clinical development and worldwide regulatory matters.

Her prior experience (during 16 years with Teva Pharmaceutical Industries), covered the clinical development and marketing plans for new CNS drugs in the USA and Europe. Specifically, she had a major role in the development, approval, and launch of rasagiline (Azilect). Her work involved leading the global clinical trials of rasagiline for Parkinson's disease as well as guiding product information, medical training, and other medico-marketing tasks.

She helped to design the rasagiline neuroprotection study for Parkinson’s disease (the ADAGIO delayed-start study), the report of which was published in the New England Journal of Medicine in 2009. Dr. Oren is one of the co-inventors recognized in the patent application related to this innovative clinical trial.